Private biotech never had it so good. Although the number of startups formed did not increase dramatically, the sector grew in size and received much more money than in 2013.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Systematic Reviews Open Access 26 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huggett, B. Biotech's wellspring—a survey of the health of the private sector in 2014. Nat Biotechnol 33, 470–477 (2015). https://doi.org/10.1038/nbt.3218
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3218